Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
135 hedge funds and large institutions have $722M invested in Clovis Oncology, Inc. in 2016 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 41 closing their positions.
93% more call options, than puts
Call options by funds: $70.5M | Put options by funds: $36.6M
14% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 42
14% less funds holding
Funds holding: 157 → 135 (-22)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
48% less capital invested
Capital invested by funds: $1.39B → $722M (-$673M)
49% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$27.6M |
| 2 |
Renaissance Technologies
New York
|
+$10.9M |
| 3 |
HM
HealthCor Management
New York
|
+$10.1M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$7.36M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$30.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.3M |
| 3 |
Millennium Management
New York
|
-$18.7M |
| 4 |
Goldman Sachs
New York
|
-$17.9M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$4.47M |
CLVS Hedge Fund Activity: Q1 2016 in Review
135 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2016, worth a combined $722M — down 48% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CLVS and 21 opened new positions — a net loss of 20 holders — while 42 trimmed existing stakes and 48 added.
The largest buyer was Redmile Group, adding an estimated $27.6M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $30.1M sold.
- 135 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2016, down from 157 in Q4 2015.
- Funds reported $722M of Clovis Oncology, Inc. stock for Q1 2016, down 48% quarter-over-quarter.
- 21 funds opened new Clovis Oncology, Inc. positions in Q1 2016 and 41 closed out, a net change of -20 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2016 was Redmile Group, an estimated $27.6M added.
- The largest Clovis Oncology, Inc. seller in Q1 2016 was Balyasny Asset Management, an estimated $30.1M sold.
Based on aggregated 13F filings for Q1 2016.